Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 271


A 'rule of 0.5' for the metabolite-likeness of approved pharmaceutical drugs.

O Hagan S, Swainston N, Handl J, Kell DB.

Metabolomics. 2015;11(2):323-339. Epub 2014 Sep 19.


Membrane transporter engineering in industrial biotechnology and whole cell biocatalysis.

Kell DB, Swainston N, Pir P, Oliver SG.

Trends Biotechnol. 2015 Mar 3. pii: S0167-7799(15)00024-4. doi: 10.1016/j.tibtech.2015.02.001. [Epub ahead of print] Review.


Molecular phenotyping of a UK population: defining the human serum metabolome.

Dunn WB, Lin W, Broadhurst D, Begley P, Brown M, Zelena E, Vaughan AA, Halsall A, Harding N, Knowles JD, Francis-McIntyre S, Tseng A, Ellis DI, O'Hagan S, Aarons G, Benjamin B, Chew-Graham S, Moseley C, Potter P, Winder CL, Potts C, Thornton P, McWhirter C, Zubair M, Pan M, Burns A, Cruickshank JK, Jayson GC, Purandare N, Wu FC, Finn JD, Haselden JN, Nicholls AW, Wilson ID, Goodacre R, Kell DB.

Metabolomics. 2015;11:9-26. Epub 2014 Jul 25.


The virtue of innovation: innovation through the lenses of biological evolution.

Kell DB, Lurie-Luke E.

J R Soc Interface. 2015 Feb 6;12(103). pii: 20141183. doi: 10.1098/rsif.2014.1183.


Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently.

Currin A, Swainston N, Day PJ, Kell DB.

Chem Soc Rev. 2015 Feb 23;44(5):1172-239. doi: 10.1039/c4cs00351a.


What would be the observable consequences if phospholipid bilayer diffusion of drugs into cells is negligible?

Kell DB.

Trends Pharmacol Sci. 2015 Jan;36(1):15-21. doi: 10.1016/ Epub 2014 Nov 10.


Eryptosis as a marker of Parkinson's disease.

Pretorius E, Swanepoel AC, Buys AV, Vermeulen N, Duim W, Kell DB.

Aging (Albany NY). 2014 Oct;6(10):788-819.


How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion.

Kell DB, Oliver SG.

Front Pharmacol. 2014 Oct 31;5:231. doi: 10.3389/fphar.2014.00231. eCollection 2014. Review.


Evidence that multiple defects in lipid regulation occur before hyperglycemia during the prodrome of type-2 diabetes.

Anderson SG, Dunn WB, Banerjee M, Brown M, Broadhurst DI, Goodacre R, Cooper GJ, Kell DB, Cruickshank JK.

PLoS One. 2014 Sep 3;9(9):e103217. doi: 10.1371/journal.pone.0103217. eCollection 2014.


SpeedyGenes: an improved gene synthesis method for the efficient production of error-corrected, synthetic protein libraries for directed evolution.

Currin A, Swainston N, Day PJ, Kell DB.

Protein Eng Des Sel. 2014 Sep;27(9):273-80. doi: 10.1093/protein/gzu029. Epub 2014 Aug 9.


Event-based text mining for biology and functional genomics.

Ananiadou S, Thompson P, Nawaz R, McNaught J, Kell DB.

Brief Funct Genomics. 2014 Jun 6. pii: elu015. [Epub ahead of print]


GeneGenie: optimized oligomer design for directed evolution.

Swainston N, Currin A, Day PJ, Kell DB.

Nucleic Acids Res. 2014 Jul;42(Web Server issue):W395-400. doi: 10.1093/nar/gku336. Epub 2014 Apr 29.


Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases.

Pretorius E, Kell DB.

Integr Biol (Camb). 2014 May;6(5):486-510. doi: 10.1039/c4ib00025k. Review.


Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells.

Kell DB, Pretorius E.

Metallomics. 2014 Apr;6(4):748-73. doi: 10.1039/c3mt00347g.


Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

Pretorius E, Bester J, Vermeulen N, Lipinski B, Gericke GS, Kell DB.

PLoS One. 2014 Jan 9;9(1):e85271. doi: 10.1371/journal.pone.0085271. eCollection 2014.


High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer's disease.

Bester J, Buys AV, Lipinski B, Kell DB, Pretorius E.

Front Aging Neurosci. 2013 Dec 6;5:88. doi: 10.3389/fnagi.2013.00088. eCollection 2013.


Path2Models: large-scale generation of computational models from biochemical pathway maps.

Büchel F, Rodriguez N, Swainston N, Wrzodek C, Czauderna T, Keller R, Mittag F, Schubert M, Glont M, Golebiewski M, van Iersel M, Keating S, Rall M, Wybrow M, Hermjakob H, Hucka M, Kell DB, Müller W, Mendes P, Zell A, Chaouiya C, Saez-Rodriguez J, Schreiber F, Laibe C, Dräger A, Le Novère N.

BMC Syst Biol. 2013 Nov 1;7:116. doi: 10.1186/1752-0509-7-116.


Yeast cells with impaired drug resistance accumulate glycerol and glucose.

Dikicioglu D, Oc S, Rash BM, Dunn WB, Pir P, Kell DB, Kirdar B, Oliver SG.

Mol Biosyst. 2014 Jan;10(1):93-102. doi: 10.1039/c2mb25512j.


Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery.

Kell DB, Goodacre R.

Drug Discov Today. 2014 Feb;19(2):171-82. doi: 10.1016/j.drudis.2013.07.014. Epub 2013 Jul 26. Erratum in: Drug Discov Today. 2014 Nov;19(11):1828.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk